Changes of immune cells and their subsets in lungs of interleukin (IL)-33-induced allergen-independent murine model of asthma

doi:10.3969/j.issn.1006-7795.2016.05.001

Abstract

Abstract: Objective To explore effects of IL-33 on subsets of T cells and B cells, type 2 innate lymphoid cells (ILC2) and natural killer T (NKT) cells in lungs in IL-33-induced murine model of asthma.Methods Mice were randomly distributed into two groups including normal saline(NS, control group) and IL-33-challenged groups. Nasal challenges with recombinant mouse IL-33 or saline were daily performed from the day 1-6,followed by every 2 days for a further 12 days. Lung functions and histological staining of lung tissue sections were used to measure airways hyperresponsiveness and inflammation.Flow cytometry was employed to determine the changes of total and phenotypes of subsets of pulmonary T cells and B cells,NKT cells and ILC2 cells, compared with those of lung. Results Compared with the NS group intranasal challenge with IL-33 induced airways hyperresponsiveness, infiltrating inflammatory cells and goblet cell hyperplasia. IL-33-challenge also increased total pulmonary numbers of cells, total CD3⁺T cells and type 2 helper cells (CD3⁺CD8^-IL-4⁺) which leading to decrease of Th1/Th2 ratio (P<0.01). In addition, nasal challenge with IL-33 increased total number of CD19⁺B cells and their subsets (B1a:CD19⁺CD23^-CD5⁺CD11b⁺, B1b:CD19⁺CD23^-CD5^-CD11b⁺ and B2 B cells:CD19⁺CD23⁺B220⁺) as well as ILC2(lineage-ICOS⁺ST2⁺) (P<0.01), but not NKT cells (CD3⁺CD8^-CD49b⁺) (P>0.05).Conclusion Local challenge with IL-33 may play role in the pathogenesis of asthma through acting directly and/or indirectly on T cells, B cells and ILC2 cells, breaking the balance of immune system and causing immune dysfunction.

Key words: interleukin-33, asthma, T lymphocytes, B lymphocytes, type 2 innate lymphoid cells

CLC Number:

R392

Yuan Linjie, Chen Shihao, An Gao, Huang Qiong, Yi Dawei, Li Yan, Lyu Zhe, Wang Jingjing, Huang Kewu, Wang Wei, Sun Ying. Changes of immune cells and their subsets in lungs of interleukin (IL)-33-induced allergen-independent murine model of asthma[J]. Journal of Capital Medical University, 2016, 37(5): 561-567.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.05.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I5/561

References

[1] Lambrecht B N, Hammad H. Asthma:The importance of dysregulated barrierimmunity[J].Eur J Immunol, 2013, 43(12):3125-3137.
[2] Nabe T. Interleukin (IL)-33:New therapeutic target for atopic diseases[J]. J Pharmacol Sci, 2014, 126(2):85-91.
[3] Li Y, Wang W, Huang P, et al. Distinct sustained structural and functional effects of interleukin-33 and interleukin-25 on the airways in a murine asthma surrogate[J]. Immunology, 2015, 145(4):508-518.
[4] Saluja R, Ketelaar M E, Hawro T, et al. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders[J]. Mol Immunol, 2015, 63(1):80-85.
[5] Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases[J]. Biochem Biophys Res Commun, 2001, 284(5):1104-1108.
[6] Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation[J]. Am J Respir Crit Care Med, 2001, 164(2):277-281.
[7] Tajima S, Oshikawa K, Tominaga S, et al. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis[J]. Chest, 2003, 124(4):1206-1214.
[8] Prefontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma[J]. J Allergy Clin Immunol, 2010, 125(3):752-754.
[9] Hamzaoui A, Berraies A, Kaabachi W, et al. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children[J]. J Asthma, 2013, 50(8):803-809.
[10] Kamijo S, Takeda H, Tokura T, et al. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation[J]. J Imunol, 2013, 190(9):4489-4499.
[11] Halim T Y, Steer C A, Matha L, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation[J]. Immunity, 2014, 40(3):425-435.
[12] Zoltowska A M, Lei Y, Fuchs B, et al. The interleukin-33 receptor ST2 is important for the development ofperipheral airway hyperresponsiveness and inflammation in a house dustmite mouse model of asthma[J]. Clin Exp Allergy, 2016, 46(3):479-490.
[13] Peine M, Marek R M, L hning M. IL-33 in T cell differentiation, function, and immune homeostasis[J]. Trends Immunol, 2016, 37(5):321-333.
[14] Shim J U, Rhee J H, Jeong J U, et al. Flagellin modulates the function of invariant NKT cells from patients with asthma via dendritic cells[J]. Allergy Asthma Immunol Res, 2016, 8(3):206-215.
[15] Walzer T, Blery M, Chaix J, et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46[J]. Proc Nat Acad Sci USA, 2007, 104(9):3384-3389.
[16] Li B W, Hendriks R W. Group 2 innate lymphoid cells in lung inflammation[J]. Immunology,2013, 140(3):281-287.
[17] Sattler S, Ling G S, Xu D, et al. IL-10-producing regulatory B cells induced by IL-33(BregIL-33) effectively attenuate mucosal inflammatory responses in the gut[J]. J Autoimmun, 2014, 50(100):107-122.
[18] Haas K M, Poe J C, Steeber D A, et al. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae[J]. Immunity, 2005, 23(1):7-18.
[19] Alugupalli K R, Leong J M, Woodland R T, et al. B1b lymphocytes confer T cell-independent long-lasting immunity[J]. Immunity, 2004, 21(3):379-390.
[20] Komai-Koma M, Gilchrist D S, Mckenzie A N, et al. IL-33 activates B1 cells and exacerbates contact sensitivity[J]. J Immunol, 2011, 186(4):2584-2591.